Mizuho Begins Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Investment analysts at Mizuho began coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report issued on Friday,Benzinga reports. The firm set an “outperform” rating and a $8.00 price target on the stock. Mizuho’s price objective points to a potential upside of 75.05% from the stock’s current price.

ZNTL has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Wall Street Zen raised Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, Guggenheim upped their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.14.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $4.57 on Friday. The stock’s 50 day moving average is $4.09 and its 200 day moving average is $3.34. The firm has a market cap of $325.34 million, a P/E ratio of -2.64 and a beta of 1.92. Zentalis Pharmaceuticals has a one year low of $1.21 and a one year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Equities analysts anticipate that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. 5AM Venture Management LLC grew its holdings in Zentalis Pharmaceuticals by 705.7% in the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after purchasing an additional 3,457,913 shares during the period. Millennium Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares during the period. Renaissance Technologies LLC grew its stake in shares of Zentalis Pharmaceuticals by 24.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after buying an additional 558,390 shares during the period. Finally, Bank of America Corp DE increased its position in Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.